» Authors » Yoshikazu Uenosono

Yoshikazu Uenosono

Explore the profile of Yoshikazu Uenosono including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 136
Citations 1983
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Nakada K, Kawashima Y, Kinami S, Fukushima R, Yabusaki H, Seshimo A, et al.
World J Gastrointest Surg . 2021 Jun; 13(5):461-475. PMID: 34122736
Background: The effects of various gastrectomy procedures on the patient's quality of life (QOL) are not well understood. Thus, this nationwide multi-institutional cross-sectional study using the Postgastrectomy Syndrome Assessment Scale-45...
12.
Arigami T, Matsushita D, Okubo K, Sasaki K, Noda M, Kita Y, et al.
Surg Today . 2021 Jun; 51(11):1851-1859. PMID: 34115210
Purpose: To assess the clinical indications for, and prognostic impact of surgery after, chemotherapy for type 4 gastric cancer. Methods: The subjects of this retrospective study were 67 patients who...
13.
Arigami T, Matsushita D, Okubo K, Sasaki K, Tsuruda Y, Kita Y, et al.
Anticancer Res . 2021 Jun; 41(6):3099-3107. PMID: 34083303
Background/aim: To determine the prognostic utility of trastuzumab-based chemotherapy based on human epidermal growth factor receptor 2 (HER2) expression in patients with para-aortic lymph node (PAN) metastasis from gastric cancer....
14.
Matsushita D, Uenosono Y, Arigami T, Yanagita S, Okubo K, Kijima T, et al.
Cancer Chemother Pharmacol . 2021 Feb; 87(6):789-797. PMID: 33641065
Purpose: The prognosis of metastatic gastric cancer has improved due to trastuzumab in patients with HER2 positive. Circulating tumor cells (CTCs) have been examined as a prognostic predictor in gastric...
15.
Okubo K, Arigami T, Matsushita D, Kijima T, Shimonosono M, Uenosono Y, et al.
BMC Cancer . 2021 Jan; 21(1):95. PMID: 33485312
Background: Postoperative complications have been linked to the morbidity and mortality of several cancers. However, predicting whether complications will occur in the early period after surgery or not is challenging....
16.
Matsushita D, Arigami T, Okubo K, Sasaki K, Noda M, Kita Y, et al.
Cancers (Basel) . 2020 Oct; 12(10). PMID: 33096708
Esophageal cancer is among the most aggressive diseases, and circulating tumor cells (CTCs) have been recognized as novel biomarkers for various cancers over the past two decades, including esophageal cancer....
17.
Arigami T, Matsushita D, Okubo K, Sasaki K, Noda M, Kita Y, et al.
Oncology . 2020 Sep; 98(11):798-806. PMID: 32906117
Objective: Although chemotherapy has been clinically recommended as the initial treatment for patients with peritoneal dissemination of gastric cancer, poor prognosis has been noted among the same patients. However, the...
18.
Arigami T, Matsushita D, Okubo K, Yanagita S, Ehi K, Sasaki K, et al.
Oncology . 2020 May; 98(9):630-636. PMID: 32428899
Objective: Nivolumab is recommended as a third-line treatment in patients with unresectable advanced or recurrent gastric cancer. Although recent studies have demonstrated the prognostic impact of salvage chemotherapy after immune...
19.
Okubo K, Arigami T, Matsushita D, Sasaki K, Kijima T, Noda M, et al.
Gastric Cancer . 2020 Feb; 23(4):746-753. PMID: 32086650
Background: The usefulness of sentinel node navigation surgery (SNNS) for early gastric cancer has been demonstrated in a multicenter prospective study. However, quality of life (QOL) after local resection remains...
20.
Arigami T, Matsushita D, Okubo K, Kawasaki Y, Iino S, Sasaki K, et al.
Oncology . 2020 Feb; 98(5):273-279. PMID: 32062663
Objective: Chemotherapy is generally recommended as the first-line standard treatment in patients with liver metastasis from gastric cancer. However, the clinical impact of surgical treatment remains unclear in responders after...